SHL Medical to showcase self-injection innovation at PODD 2025

• Maggie™, our cartridge-based autoinjectors, tailored for large-volume subcutaneous drug delivery. 

• Elexy™, our award-winning electromechanical autoinjector, featuring a reusable power unit compatible with a pre-filled syringe or a cartridge.

Rounding out the portfolio, we will also be unveiling a new autoinjector, offering visitors something different to discover.

Our participation at PODD this year also includes a featured leadership session, “Pushing the Limits: What It Will Take to Inject More”, where SHL Medical’s Alex Lyness, PhD will address what is required to subcutaneously self-inject longer-acting and more complex drug formulations beyond the conventional 1.0 to 2.0 mL dose volume range.

With a growing manufacturing footprint in the US, SHL Medical continues to strengthen our end-to-end services, from device design to final assembly, enabling pharma partners to accelerate timelines, reduce tech transfer risk, and scale their combination product development with greater proximity and operational flexibility. Our team will be available on-site to discuss how these capabilities align with pharma’s development and manufacturing goals. 

Register today and meet us at PODD in Boston to explore how SHL Medical’s self-injection solutions and device development services can support your next combination product program.